• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by American Well Corporation

    2/28/25 4:46:04 PM ET
    $AMWL
    Business Services
    Consumer Discretionary
    Get the next $AMWL alert in real time by email
    S-8 1 dp225482_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on February 28, 2025

    Registration No. 333- 

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    AMERICAN WELL CORPORATION

    (Exact Name of Registrant as Specified in its Charter)

     

    Delaware 7372 20-5009396
    (State or Other Jurisdiction of
    Incorporation or Organization)
    (Primary Standard Industrial Classification Code Number) (I.R.S. Employer
    Identification No.)
     

    75 State Street, 26th Floor 

    Boston, MA 02109 

     
    (Address of Principal Executive Offices)

     

     

     

    American Well Corporation 2020 Equity Incentive Plan

    American Well Corporation 2020 Employee Stock Purchase Plan

    (Full Titles of the Plans)

     

     

    Ido Schoenberg 

    Chairman, Chief Executive Officer 

    American Well Corporation

    75 State Street, 26th Floor

    Boston, MA 02109

    (617) 204-3500 

    (Name, Address, Including Zip Code, and Telephone Number,
    Including Area Code, of Agent For Service)

     

     

     

     

    With copies to:

    Adam Kaminsky

    Michael Kaplan
    Davis Polk & Wardwell LLP
    450 Lexington Avenue
    New York, New York 10017
    (212) 450-4000

     

    Bradford Gay 

    SVP, General Counsel
    American Well Corporation
     

    75 State Street, 26th Floor 

    Boston, MA 02109 

    (617) 204-3500  

     

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer, ” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.  

     

    Large accelerated filer ☐ Accelerated filer ☒
    Non-accelerated filer ☐ (Do not check if a smaller reporting company) Smaller reporting company ☐
      Emerging Growth Company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

    EXPLANATORY NOTE

     

    Pursuant to General Instruction E to Form S-8, American Well Corporation (the “Registrant”) is filing this Registration Statement on Form S-8 (this “Registration Statement”) with the U.S. Securities and Exchange Commission (the “Commission”) to register additional shares of Class A common stock, $0.01 par value per share, of the Registrant (“Class A Common Stock”) for issuance under the 2020 Equity Incentive Plan (the “2020 Plan”) and the 2020 Employee Stock Purchase Plan (“2020 ESPP”). The number of shares of Class A Common Stock available for issuance under the 2020 Plan is subject to an annual increase on the first day of each calendar year beginning on January 1, 2021 and ending on (and including) January 1, 2029 by an amount equal to the lesser of (i) five percent (5%) of the number of shares of all classes of the Registrant’s common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such smaller number of shares of all classes of the Registrant’s common stock as determined by the Registrant’s Board of Directors (the “Board”) (the “2020 Plan Evergreen Provision”). The number of shares of Class A Common Stock available for issuance under the 2020 ESPP is subject to an annual increase on the first day of each calendar year beginning on January 1, 2021 and ending on (and including) January 1, 2029 by an amount equal to the least of (i) one percent (1%) of the number of shares of Class A Common Stock outstanding as of the date on which the registration statement covering the initial public offering of Class A Common Stock was declared effective by the Commission, (ii) one percent (1%) of number of shares of all classes of the Registrant’s common stock outstanding on the final day of the immediately preceding calendar year or (iii) such smaller number of shares of Class A Common Stock as determined by the Board (the “ESPP Evergreen Provision”). On January 1, 2025, the number of shares of Class A Common Stock available for issuance pursuant to the 2020 Plan Evergreen Provision and the ESPP Evergreen Provision increased by 764,620 and 99,082 shares, respectively (the “2025 Evergreen Shares”). This Registration Statement registers the 2025 Evergreen Shares.

     

    This Registration Statement hereby incorporates by reference the contents of the Registrant’s Registration Statements on Form S-8 filed with the Commission on September 18, 2020 (File No. 333-248894), on June 24, 2022 (File No. 333-265834), on October 6, 2023 (File No. 333-274896) and on February 16, 2024 (File No. 333-277153), to the extent not superseded hereby.

     

     

     

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by the Registrant with the Commission under the Securities Act of 1933, as amended (the “Securities Act”) or the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:

     

    (a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by the Registrant with the Commission on February 12, 2025, which contains the Company’s audited financial statements for the latest fiscal year for which such statements have been filed; and

     

    (d) The description of the Registrant’s securities included in Exhibit 4.7 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

     

    In addition, all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than documents or any information therein deemed to have been furnished and not filed in accordance with rules of the Commission), prior to the filing of a post-effective amendment to this Registration Statement, which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein (or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein), modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 8.  Exhibits.

     

    Exhibit
    Number 

     
    4.1 Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Registrant’s Amendment No. 1 to Registration Statement on Form S-1, No. 333-248309, filed on September 8, 2020)
    4.2 Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Registrant's Current Report on Form 8-K, No. 001-39515, filed on July 15, 2024)
    4.3 Bylaws (incorporated by reference to Exhibit 3.2 of the Registrant’s Amendment No. 1 to Registration Statement on Form S-1, No. 333-248309, filed on September 8, 2020)
    4.4 Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 of the Registrant’s Registration Statement on Form S-1, No. 333-248309, filed on August 24, 2020)
    4.5 Second Amended and Restated Investors’ Rights Agreement, dated October 8, 2010, as amended on November 1, 2016, May 29, 2018 and September 5, 2019 (incorporated by reference to Exhibits 4.2, 4.3, 4.4 and 4.5 of the Registrant’s Registration Statement on Form S-1, No. 333-248309, filed on August 24, 2020) and Amendment No. 5 and Joinder to Second Amended and Restated Investors’ Right Agreement, dated September 21, 2020 (incorporated by reference to Exhibit 10.1 of the Registrations Current Report on Form 8-K, No. 001-39515, filed on September 22, 2020)

     

    3

     

    Exhibit
    Number 

     
    5.1* Opinion of Davis Polk & Wardwell LLP
    23.1* Consent of PricewaterhouseCoopers LLP
    23.2* Consent of Davis Polk & Wardwell LLP (included in Exhibit 5.1)
    24.1* Powers of Attorney (included on signature page)
    99.1 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 of the Registrant’s Registration Statement on Form S-1, No. 333-248309, filed on August 24, 2020)
    99.3 2020 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.23 of the Registrant’s Registration Statement on Form S-1, No. 333-248309, filed on August 24, 2020)
    107* Filing Fee Table

     

     

    *       Filed herewith.

     

    4

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant, American Well Corporation, certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on the 28th day of February, 2025.

     

     

    AMERICAN WELL CORPORATION

       
       
      By: /s/ Ido Schoenberg
        Name: Ido Schoenberg
        Title: Chairman and Chief Executive Officer

     

    5

     

    POWER OF ATTORNEY AND SIGNATURES

     

    Know all persons by these presents, that each person whose signature appears below constitutes and appoints Ido Schoenberg, Roy Schoenberg and Bradford Gay, and each of them, as his or her true and lawful attorney-in-fact and agents, upon the action of such appointee, with full power of substitution and resubstitution, to do any and all acts and things and execute, in the name of the undersigned, any and all instruments which each of said attorneys-in-fact and agents may deem necessary or advisable in order to enable American Well Corporation to comply with the Securities Act, and any requirements of the Commission in respect thereof, in connection with the filing with the Commission of this Registration Statement under the Securities Act, including specifically but without limitation, power and authority to sign the name of the undersigned to such Registration Statement, and any amendments to such Registration Statement (including post-effective amendments), and to file the same with all exhibits thereto and other documents in connection therewith, with the Commission, to sign any and all applications, registration statements, notices or other documents necessary or advisable to comply with applicable state securities laws, and to file the same, together with other documents in connection therewith with the appropriate state securities authorities, granting unto each of said attorneys-in-fact and agents full power and authority to do and to perform each and every act and thing requisite or necessary to be done in and about the premises, as fully and to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

     

    Signature

     

    Title

     

    Date

             
    /s/ Ido Schoenberg   Chairman and Chief Executive Officer   February 28, 2025

    Ido Schoenberg, MD

     

    (Principal Executive Officer and Director) 

     
             
    /s/ Mark Hirschhorn   Chief Financial Officer   February 28, 2025

    Mark Hirschhorn

     

    (Principal Financial Officer)

     
             
    /s/ Paul McNeice   Chief Accounting Officer   February 28, 2025

    Paul McNeice

     
    (Principal Accounting Officer)
     
            February 28, 2025
    /s/ Roy Schoenberg, MD, MPH   Director  
    Roy Schoenberg, MD, MPH        
             
    /s/ Rivka Goldwasser   Director   February 28, 2025

    Rivka Goldwasser

     

     
             
    /s/ Stephen Schlegel   Director   February 28, 2025

    Stephen Schlegel

       
             
    /s/ Dr. Peter Slavin   Director   February 28, 2025

    Dr. Peter Slavin

       
             
    /s/ Derek Ross   Director   February 28, 2025

    Derek Ross

       
             
    /s/ Dr. Delos (Toby) Cosgrove   Director   February 28, 2025

    Dr. Delos (Toby) Cosgrove

       
             
    /s/ Deborah Jackson   Director   February 28, 2025

    Deborah Jackson

       
             
    /s/ Rob Webb   Director   February 28, 2025

    Rob Webb

       

     

     

    Get the next $AMWL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMWL

    DatePrice TargetRatingAnalyst
    1/13/2025$15.00Equal Weight → Overweight
    Wells Fargo
    8/3/2023$5.00 → $2.50Overweight → Equal-Weight
    Morgan Stanley
    3/23/2023$5.00 → $2.50Outperform → Market Perform
    TD Cowen
    2/27/2023$5.00 → $3.50Overweight → Neutral
    Piper Sandler
    1/4/2023$4.20Neutral → Buy
    BofA Securities
    9/7/2022$5.00Hold
    Truist
    4/14/2022$6.00Buy
    Guggenheim
    4/1/2022$5.00Neutral
    Credit Suisse
    More analyst ratings

    $AMWL
    Financials

    Live finance-specific insights

    See more
    • Amwell® Announces Results for First Quarter 2025

      BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL) a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the first quarter ended March 31. Visit Amwell's investor relations website at investors.amwell.com to view the first quarter 2025 earnings report. The company will host a conference call to discuss its financial results today at 5 p.m. ET, May 1. The call can be accessed via a live audio webcast at https://edge.media-server.com/mmc/p/9tn5fcf6. A replay of the call will be available via webcast shortly after the completion of the call, at investors.amwell.com. About Amwell Amwell offers payers and

      5/1/25 4:05:00 PM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • Amwell® to report first quarter 2025 operating results

      BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in digital care, will report first quarter 2025 operating results after stock market trading hours on Thursday, May 1 2025. Following the distribution of the earnings alert via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update. The full earnings report and the live audio webcast can be accessed by visiting the Investors section of the company's website. A webcast replay of the call will be available at investors.amwell.com for approximately 90 days. About Amwell  Amwell offers payers and

      4/17/25 7:05:00 AM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • Amwell® Announces Results for Fourth Quarter and Full Year 2024

      BOSTON, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the fourth quarter and full year ended Dec. 31, 2024. Visit Amwell's investor relations website at investors.amwell.com to view the fourth quarter and full year 2024 earnings report. The company will host a conference call to discuss its financial results today at 5 p.m. ET, Feb. 12. The call can be accessed via a live audio webcast at https://edge.media-server.com/mmc/p/zsp4abpw. A replay of the call will be available via webcast shortly after the completion of the call, at investors.amwell.com. Abo

      2/12/25 4:05:00 PM ET
      $AMWL
      Business Services
      Consumer Discretionary

    $AMWL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Amwell makes grant to new employee under inducement plan

      BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading technology-enabled care platform provider, announced that on May 6, Amwell made a grant of RSUs of 3,451 shares of its Class A common stock to one new employee. The grant was offered as material inducement to the employee's employment with Amwell. The RSUs will vest as follows, subject to the employee's continued employment through the applicable vesting date: 25% of the RSUs will vest upon the first anniversary of the grant date ("Initial Vesting Date"), and the remaining 75% of the RSUs will vest in equal pro rata increments every three months thereafter (beginning on the first calendar day of the month following the

      5/6/25 4:05:00 PM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • Amwell® Announces Results for First Quarter 2025

      BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL) a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the first quarter ended March 31. Visit Amwell's investor relations website at investors.amwell.com to view the first quarter 2025 earnings report. The company will host a conference call to discuss its financial results today at 5 p.m. ET, May 1. The call can be accessed via a live audio webcast at https://edge.media-server.com/mmc/p/9tn5fcf6. A replay of the call will be available via webcast shortly after the completion of the call, at investors.amwell.com. About Amwell Amwell offers payers and

      5/1/25 4:05:00 PM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • Amwell® to participate in upcoming investor conferences

      BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will participate in the following upcoming investor conferences:   On May 8, Mark Hirschhorn, chief financial officer and chief operating officer, will participate in one-on-one meetings at the Needham & Co. Virtual Technology and Services Conference held virtually. On June 24, Hirschhorn will participate in the Truist Securities Healthcare Disruptors & Digital Health Conference in New York City.    About Amwell Amwell offers payers and health systems a single, comprehensive, technology-enabled care platform. We use technolo

      4/24/25 7:30:00 AM ET
      $AMWL
      Business Services
      Consumer Discretionary

    $AMWL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Mcneice Paul Francis sold $747 worth of shares (113 units at $6.61), decreasing direct ownership by 0.78% to 14,366 units (SEC Form 4)

      4 - American Well Corp (0001393584) (Issuer)

      6/4/25 5:01:52 PM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • President, International Gotlib Phyllis sold $31,628 worth of shares (4,782 units at $6.61), decreasing direct ownership by 3% to 141,849 units (SEC Form 4)

      4 - American Well Corp (0001393584) (Issuer)

      6/4/25 5:01:14 PM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • President, International Gotlib Phyllis sold $2,155 worth of shares (299 units at $7.21), decreasing direct ownership by 0.20% to 146,631 units (SEC Form 4)

      4 - American Well Corp (0001393584) (Issuer)

      5/5/25 4:31:36 PM ET
      $AMWL
      Business Services
      Consumer Discretionary

    $AMWL
    Leadership Updates

    Live Leadership Updates

    See more

    $AMWL
    SEC Filings

    See more

    $AMWL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amwell announces new chief financial officer

      BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in digital care, today announced Mark Hirschhorn will become Amwell Chief Financial Officer (CFO) effective Oct. 21, succeeding Robert "Bob" Shepardson, who has been in the role since 2021. Hirschhorn will oversee Amwell's financial operations, enterprisewide optimization and capital allocation activities, and will play a meaningful leadership role in guiding the company's strategy to support its long-term growth objectives and enhance shareholder value.   Hirschhorn is a healthcare technology industry leader, with over three decades of experience in financial and strategic operations, having served in senior executiv

      10/15/24 4:30:00 PM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • Amwell Announces Appointment of Ricky Goldwasser to its Board of Directors

      Boston, June 17, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in hybrid care enablement, today announces the appointment of Ricky Goldwasser to the company's Board of Directors, effective June 13. "Ricky brings to our board a deep financial background that makes her an invaluable addition as we focus on Amwell's path to profitability. Ricky's strong voice coupled with her impressive track record will help guide Amwell as we strive for greater efficiencies, optimized cash flow and profitable growth, while remaining committed to enabling our clients to achieve their goals. We are pleased to welcome Ricky to the team," said Ido Schoenberg, M.D., CEO and chairman, Amwell. Ms. Gol

      6/17/24 8:05:00 AM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

      ALACHUA, Fla. and TAMPA, Fla., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, is pleased to announce today the appointment of Mrs. Kathy Weiler to its Board of Directors, effective December 20, 2023. Weiler, a senior executive with 20+ years of experience and proven track record in driving strategic commercial initiatives, will serve on the Board's Governance, Nominating and Sustainability Committee, and the Quality, Compliance, and Portfolio Management Committee. "I am happy to welcome Kathy to the Board as Axogen is approaching an exciting inflection point in its journ

      12/26/23 4:15:00 PM ET
      $AMWL
      $AXGN
      Business Services
      Consumer Discretionary
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by American Well Corporation

      SCHEDULE 13G/A - American Well Corp (0001393584) (Subject)

      5/15/25 4:21:34 PM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • SEC Form 10-Q filed by American Well Corporation

      10-Q - American Well Corp (0001393584) (Filer)

      5/1/25 4:13:22 PM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • American Well Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - American Well Corp (0001393584) (Filer)

      5/1/25 4:10:12 PM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by American Well Corporation

      SC 13G/A - American Well Corp (0001393584) (Subject)

      11/12/24 4:43:25 PM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • SEC Form SC 13G filed by American Well Corporation

      SC 13G - American Well Corp (0001393584) (Subject)

      11/6/24 4:14:27 PM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • SEC Form SC 13G filed by American Well Corporation

      SC 13G - American Well Corp (0001393584) (Subject)

      11/4/24 11:53:44 AM ET
      $AMWL
      Business Services
      Consumer Discretionary

    $AMWL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amwell upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Amwell from Equal Weight to Overweight and set a new price target of $15.00

      1/13/25 7:29:38 AM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • Amwell downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Amwell from Overweight to Equal-Weight and set a new price target of $2.50 from $5.00 previously

      8/3/23 6:19:10 AM ET
      $AMWL
      Business Services
      Consumer Discretionary
    • Amwell downgraded by TD Cowen with a new price target

      TD Cowen downgraded Amwell from Outperform to Market Perform and set a new price target of $2.50 from $5.00 previously

      3/23/23 7:15:52 AM ET
      $AMWL
      Business Services
      Consumer Discretionary